1. Home
  2. QGEN

QGEN

Qiagen N.V.

Logo Qiagen N.V.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-16-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Qiagen NV offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Founded: 1986 Country:
Netherlands
Netherlands
Employees: N/A City: N/A
Market Cap: 8.8B IPO Year: 1996
Target Price: $50.51 AVG Volume (30 days): 1.1M
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: 3.35% Dividend Payout Frequency: N/A
EPS: 1.50 EPS Growth: -19.35
52 Week Low/High: $34.74 - $47.70 Next Earning Date: 04-29-2024
Revenue: $1,965,311,000 Revenue Growth: -8.23%
Revenue Growth (this year): 4.36% Revenue Growth (next year): 6.68%

Share on Social Networks: